Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Centre for Circulatory Health, Anglia Ruskin University, Cambridge, UK.
Eur J Vasc Endovasc Surg. 2023 Feb;65(2):291-297. doi: 10.1016/j.ejvs.2022.10.018. Epub 2022 Oct 17.
To identify the rate of post-thrombotic syndrome (PTS) after isolated distal deep venous thrombosis (IDDVT) by performing a meta-analysis of the rate of PTS across randomised and observational studies.
MEDLINE, Embase, the Cochrane Controlled Trials Register, Clinicaltrials.gov, European Union Clinical Trials, International Standard Randomised Controlled Trial Number, and the Australian and New-Zealand Trials Registries.
This review followed PRISMA guidelines using a registered protocol (CRD42021282136). Databases were searched up to December 2021 and prospective studies reporting the development of post-thrombotic syndrome were included; these were pooled with the meta-analysis.
The results showed a post-thrombotic rate of 17% (95% CI 11 - 26%) (seven studies, 217 cases, 1 105 participants). Heterogeneity was high (I = 89%). On meta-regression, the rate of post-thrombotic syndrome was not correlated with the length of follow up (p = .71). Three studies (302 participants) reported the severity of post-thrombotic syndrome: 78% were mild (Villalta score 5 - 9); 11% were moderate (Villalta score 10 - 14), and 11% were severe (Villalta score ≥ 15).
The risk of post-thrombotic syndrome after IDDVT was one in five and the risk of severe clinical manifestations, including ulceration, was one in 50. There was significant clinical, methodological, and statistical heterogeneity between studies and a substantial risk of bias from pooled studies. Randomised trials to support interventions for prevention of post-thrombotic syndrome are urgently needed.
通过对随机和观察性研究中 PTS 发生率的荟萃分析,确定孤立性远端深静脉血栓形成(IDDVT)后血栓后综合征(PTS)的发生率。
MEDLINE、Embase、Cochrane 对照试验登记处、Clinicaltrials.gov、欧盟临床试验、国际标准随机对照试验编号以及澳大利亚和新西兰试验登记处。
本研究遵循 PRISMA 指南,并使用了注册方案(CRD42021282136)。数据库检索截至 2021 年 12 月,纳入报告 PTS 发展的前瞻性研究;这些研究与荟萃分析一起进行汇总。
结果显示 PTS 的发生率为 17%(95%CI 11-26%)(7 项研究,217 例,1105 例参与者)。异质性很高(I=89%)。在元回归中,PTS 发生率与随访时间长短无关(p=0.71)。三项研究(302 名参与者)报告了 PTS 的严重程度:78%为轻度(Villalta 评分 5-9);11%为中度(Villalta 评分 10-14),11%为重度(Villalta 评分≥15)。
IDDVT 后 PTS 的风险为五分之一,出现溃疡等严重临床表现的风险为五十之一。研究之间存在显著的临床、方法学和统计学异质性,且汇总研究存在较大的偏倚风险。迫切需要随机试验来支持预防 PTS 的干预措施。